Clinical Trials Browser

Carcinoma × durvalumab × Gastrointestinal × Clear all

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT04379596 2026-02-23

DG-03

Phase 2 Recruiting

450 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT06027086 2026-02-12

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Phase 1/2 Recruiting

27 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma

NCT06564623 2025-12-05

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Phase 1 Recruiting

25 enrolled

Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

NCT03611556 2023-10-03

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Phase 1/2 Completed

213 enrolled 42 charts

Gastrointestinal

Carcinoma, Pancreatic Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

ROWAN

DG-03

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.